The natural course of IgG4-related ophthalmic disease after debulking surgery: a single-centre retrospective study.
debulking surgery
igg4-related ophthalmic disease
relapse rate
Journal
BMJ open ophthalmology
ISSN: 2397-3269
Titre abrégé: BMJ Open Ophthalmol
Pays: England
ID NLM: 101714806
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
03
2019
revised:
22
05
2019
accepted:
11
06
2019
entrez:
17
9
2019
pubmed:
17
9
2019
medline:
17
9
2019
Statut:
epublish
Résumé
This study aimed to examine the natural course and relapse rate of IgG4-related ophthalmic disease (IgG4-ROD) after debulking surgery in Japanese patients. This retrospective review included patients with IgG4-ROD who did not undergo further treatment following debulking surgery. The patients were diagnosed between January 2009 and December 2018 at the Department of Ophthalmology and Pathology, Niigata University Medical and Dental Hospital. The main outcome measures included postoperative IgG4-ROD recurrence rate and differences between patients with and without recurrent disease. Fifteen patients (six male, 9 female; 61.8±16.2 years) were included. Twelve patients (80.0%) had dacryoadenitis disease and three patients (20.0%) had orbital fat tissue disease. About 70%-100% of the lesion was resected in the debulking surgery and the pathological diagnosis was rendered. A definitive diagnosis was made in 13 cases (86.7%) and a probable diagnosis in 2 cases (13.3%). Patients were followed up for 39.0±25.5 months following operation. All patients had lesion volume reduction and patients with dacryoadenitis had eyelid swelling improvement after surgery. Two patients (13.3%) had disease recurrence and six patients (40.0%) had extraophthalmic lesions. There was no statistically significant difference in clinical features between relapsed and non-recurring cases. We observed a 13.3% relapse rate following debulking surgery in patients with IgG4-ROD who did not undergo further treatment. This rate is lower than the documented relapse rate of 30%-70% following oral prednisolone therapy. Therefore, debulking surgery may be a treatment option for IgG4-ROD.
Identifiants
pubmed: 31523717
doi: 10.1136/bmjophth-2019-000295
pii: bmjophth-2019-000295
pmc: PMC6711462
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000295Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Adv Anat Pathol. 2010 Sep;17(5):303-32
pubmed: 20733352
J Clin Exp Hematop. 2011;51(1):13-20
pubmed: 21628856
N Engl J Med. 2012 Feb 9;366(6):539-51
pubmed: 22316447
Acta Ophthalmol. 2013 Dec;91(8):694-700
pubmed: 22963447
Am J Ophthalmol. 2013 Feb;155(2):373-379.e1
pubmed: 23111178
Graefes Arch Clin Exp Ophthalmol. 2014 Mar;252(3):531-8
pubmed: 24384801
J Gastroenterol. 2014 Jun;49(6):961-70
pubmed: 24639058
Mod Rheumatol. 2015 Mar;25(2):199-204
pubmed: 25159154
Br J Ophthalmol. 2015 Mar;99(3):376-81
pubmed: 25185258
Eye (Lond). 2015 Jan;29(1):122-8
pubmed: 25341435
Jpn J Ophthalmol. 2015 Jan;59(1):1-7
pubmed: 25392273
Lancet. 2015 Apr 11;385(9976):1460-71
pubmed: 25481618
Ann Rheum Dis. 2015 Jun;74(6):1171-7
pubmed: 25667206
Br J Ophthalmol. 2015 Nov;99(11):1493-7
pubmed: 25947555
Curr Opin Ophthalmol. 2015 Nov;26(6):491-7
pubmed: 26367090
Medicine (Baltimore). 2017 Mar;96(10):e6205
pubmed: 28272212
Br J Ophthalmol. 2018 Jun;102(6):736-741
pubmed: 28972022
Neth J Med. 2018 Aug;76(6):275-285
pubmed: 30152392
Int J Ophthalmol. 2018 Sep 18;11(9):1539-1544
pubmed: 30225231